Platinum Based Ovarian Cancer Treatment

Platinum Based Ovarian Cancer Treatment

The platinum based ovarian cancer treatment market is expected to register a CAGR of approx. 19% over the period of 2022-2028. Platinum-based ovarian cancer treatment refers to the use of chemotherapy drugs that contain platinum to treat ovarian cancer. Platinum drugs, such as cisplatin and carboplatin are effective at killing cancer cells by damaging their DNA and preventing them from dividing. Carboplatin is the most commonly used platinum drug for ovarian cancer treatment. This type of chemotherapy is often given in combination with other chemotherapy drugs or targeted therapy drugs, depending on the stage and type of ovarian cancer. The rising incidences of ovarian cancer globally are the major attributing factor for the growth of the ovarian cancer treatment market including platinum-based treatment. For instance, according to Globocan’s 2020 projections, by 2040, the number of women around the world diagnosed with ovarian cancer will rise almost 42% to 445,721. The number of women dying from ovarian cancer each year is projected to increase to 313,617 an increase of over 50% from 2020. Furthermore, the rising number of clinical researchers on combination drugs with platinum based drugs for treatment also catalyses the growth of the market.

• Based on the drug type, the market has been categorized into cisplatin and carboplatin. Among them, the cisplatin segment is expected to grow at the highest CAGR in the market. In the case of certain forms of ovarian cancer, particularly those that are platinum-sensitive, cisplatin is superior to carboplatin in terms of therapeutic efficacy which is likely to boost the growth of the segment. For instance, according to the Journal of Clinical Oncology in 2020, cisplatin was found to be more effective than carboplatin in treating advanced ovarian cancer in patients who had not previously received platinum-based chemotherapy.
• Based on the dosage form, the market has been categorized into intravenous powder and intravenous solution. Among them, the intravenous solution segment is expected to grow at a higher CAGR in the market. Intravenous solutions are more convenient to use than intravenous powders. For medical professionals who need to administer the medication quickly and effectively, they can be a big advantage because they don't need any additional preparation time or steps.
• Based on the end-user, the market has been categorized into hospitals, cancer research institutes and others. Among them, the hospital category is to witness higher adoption of platinum-based ovarian cancer treatment during the forecast period. Hospitals frequently have more infrastructure and resources than cancer institutes, which can enable them to provide comprehensive cancer treatment services, such as platinum-based chemotherapy. In addition, hospitals may have stronger relationships with health insurance providers, making it easier for patients to access their services.
• For a better understanding of the market adoption of platinum based ovarian cancer treatment, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for the platinum based ovarian cancer treatment industry. It is characterized by a high level of competition, with several pharmaceutical companies offering platinum-based chemotherapy drugs for the treatment of ovarian cancer. Further, countries such as U.S. and Canada are present in the region, and the presence of well-established healthcare infrastructure in these countries attributes to the dominating share of North America in the global market. The North American region is currently witnessing rising incidences of ovarian cancer which is an important attributing actor for the majority share of the region in the global market. For instance, as per the American Cancer Society, about 19,710 women will receive a new diagnosis of ovarian cancer and about 13,270 women will die from ovarian cancer.
• Some of the major players operating in Eli Lilly and Co, Bristol-Myers Squibb Co, Novartis AG, Pfizer Inc., Roche Holding AG Genussscheine, AstraZeneca, Merck KGaA, Johnson & Johnson, Sanofi SA, GlaxoSmithKline plc among others. Several M&A’s along with partnerships have been undertaken.